User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study

Journal of Substance Use

Volumn 15, Issue 4, 2010, Pages 283-300

  Carhart Harris, R L ^a,b   Nutt, D J ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Hallucinogens; LSD; Psilocybin; Psychedelics

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; CANNABIS; KETAMINE; LYSERGIDE; PSILOCYBINE; PSYCHEDELIC AGENT;

ADDICTION; ANXIETY DISORDER; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUSTRALIA; BIPOLAR DISORDER; CANADA; DEMOGRAPHY; DEPRESSION; DRUG EFFECT; EUROPEAN AMERICAN; HEALTH EDUCATION; HEALTH HAZARD; HEALTH PROMOTION; HUMAN; INFORMATION; INSOMNIA; MENTAL HEALTH; MIGRAINE; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PERCEPTION DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOANALYSIS; PSYCHODYNAMICS; QUESTIONNAIRE; RACE; RESEARCH; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; UNITED KINGDOM; WEB BASED QUESTIONNAIRE; WELLBEING; WESTERN HEMISPHERE;

EID: 77955186505     PISSN: 14659891     EISSN: 14759942     Source Type: Journal    
DOI: 10.3109/14659890903271624     Document Type: Article

References (32)

1. Abramson, H. A. (1967). The Second International Conference on the Use of LSD in Psychotherapy. New York: Bobbs-Merrill Co.
2. Ashton, C. H., Moore, P. B., Gallagher, P., and Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology, 19(3), 293-300.
3. Bouso, J. C., Doblin, R., Farré, M., Alcázar, M. A., and Gómez-Jarabo, G. (2008). MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs, 40(3), 225-236.
4. Busch, A. K., and Johnson, W. C. (1950). LSD 25 as an aid in psychotherapy; preliminary report of a new drug. Diseases of the Nervous System, 11(8), 241-243.
5. Cohen, S., and Ditman, K. S. (1962). Complications associated with lysergic acid diethylamide (LSD-25). Journal of the American Medical Association, 181, 161-182.
6. Croxford, J. L. (2003). Therapeutic potential of cannabinoids in CNS disease. CNS Drugs, 17(3), 179-202.
7. Deakin, J. F., Lees, J., McKie, S., Hallak, J. E., Williams, S. R., and Dursun, S. M. (2008). Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Archives of General Psychiatry, 65(2), 154-164.
8. Doblin, R. (2002). A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. Journal of Psychoactive Drugs, 34(2), 185-194.
9. Griffiths, R. R., Bigelow, G. E., and Henningfield, J. E. (1980). Similarities in animal and human drug-taking behaviour. Advances in Substance Abuse, 1, 1-90.
10. Griffiths, R. R., Richards, W. A., McCann, U., and Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berlin), 187(3), 268-83; discussion 284-292.
11. Griffiths, R., Richards, W., Johnson, M., McCann, U., and Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol, 22, 621-632
12. Grinspoon, L., and Bakalar, J. B. (1979). Psychedelic Drugs Reconsidered. New York: Basic Books.
13. Grof, S. (1975). Realms of the Human Unconscious. Observations From LSD Research. London. Souvenir Press.
14. Halpern, J. H., and Pope, H. G., Jr (2003). Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence, 69(2), 109-119.
15. Iversen, L. (2003). Cannabis and the brain. Brain, 126(6), 1252-1270.
16. Johnson, M., Richards, W., and Griffiths, R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620.
17. Lancet Editorial (2006). Reviving research into psychedelic drugs. Lancet, 367(9518), 1214.
18. Liebrenz, M., Borgeat, A., Leisinger, R., and Stohler, R. (2007). Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Medical Weekly, 137(15-16), 234-236.
19. Mangini, M. (1998). Treatment of alcoholism using psychedelic drugs: a review of the program of research. Journal of Psychoactive Drugs, 30(4), 381-418.
20. McKeganey, N. (2009). The classification of ecstasy is not a black-and-white issue. Retrieved January 15, 2009, from www.guardian.co.uk.
21. Mithoefer, M., Mithoefer, A., and Wagner, M. (2008). Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in subjects with chronic posttraumatic stress disorder: A Phase II clinical trial completed 19 September, 2008. Poster presented at the 24th Annual Meeting of the International Society of Traumatic Stress Studies, Chicago.
22. Moreno, F. A., Wiegand, C. B., Taitano, E. K., and Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(11), 1735-1740.
23. Morgan, C. J. A., Muettzelfeldt, L., and Curran, H. V. (2008). Reclassifying psychoactive substances on the basis of their actual harms: an internet survey of drug users [Abstract]. Journal of Psychopharmacology, 22(5), S05.
24. Murphy, P. N. (2007). Assessing drug-related harm. Lancet, 369(9576), 1856.
25. Nutt, D. J. (2009). Equasy-an overlooked addiction with implications for the current debate on drug harms. Journal of Psychopharmacology, 23(1), 3-5.
26. Nutt, D., King, L. A., Saulsbury, W., and Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. Lancet, 369(9566), 1047-1053.
27. Sandison, R. A. (1954). Psychological aspects of the LSD treatment of the neuroses. Journal of Mental Science, 100(419), 508-515.
28. Selvaraj, S., Hoshi, R., Bhagwagar, Z., Murthy, N. V., Hinz, R., Cowen, P., Curran, H. V., and Grasby, P. (2009). Brain serotonin transporter binding in former users of MDMA (ecstasy). British Journal of Psychiatry, 194(4), 355-359.
29. Sessa, B. (2005). Can psychedelics have a role in psychiatry once again? British Journal of Psychiatry, 186, 457-458.
30. Sessa, B., and Nutt, D. J. (2007). MDMA, politics and medical research: have we thrown the baby out with the bathwater? Journal of Psychopharmacology, 21(8), 787-791.
31. Sewell, R. A., Halpern, J. H., and Pope, H. G., Jr (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12), 1920-1922.
32. Zarate, C. A., Jr, Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., and Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856-864.